ID93 + GLA-SE

BIOLOGICAL4 trials

Sponsors

Access to Advanced Health Institute (AAHI)

Conditions

Pulmonary TBPulmonary Tuberculosis

Phase 1

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

CompletedNCT01599897

Access to Advanced Health Institute (AAHI)Pulmonary Tuberculosis

Start: 2012-08-31End: 2014-05-31Updated: 2017-09-15

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

CompletedNCT01927159

Access to Advanced Health Institute (AAHI)Pulmonary Tuberculosis

Start: 2013-09-30End: 2015-07-31Updated: 2018-02-01

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

CompletedNCT03722472

Access to Advanced Health Institute (AAHI)Pulmonary TB

Start: 2018-10-02End: 2020-06-15Updated: 2023-06-01

Phase 2

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

CompletedNCT02465216

Access to Advanced Health Institute (AAHI)Pulmonary Tuberculosis

Start: 2015-06-30End: 2017-01-31Updated: 2019-03-12

Related Papers

Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans

Frontiers in Immunology2024-09-241 citations

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.

2023-03-0623 citations

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.

2020-12-0871 citations

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

2018-09-04133 citations

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

2018-04-01112 citations